Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE